U.S. regulators have antitrust concerns.
The deal, announced last week, would created a drugstore behemoth with 12,600 U.S. retail locations, easily dwarfing the 8,000 locations of CVS Health’s CVS network. If Walgreens did shut 1,000 of its own or Rite Aid’s stores, that would be 8% of its total store count. (CVS will operate nearly 10,000 locations once its acquisition of Target’s TGT pharmacy is completed.) However, in a presentation to investors Walgreens filed with U.S. regulators on Monday, the company said it did not expect the closings to exceed half that amount, or 500 stores.
It would be challenging for Walgreens to find buyers for those stores. After Walgreens, CVS, and Rite Aid, there are no national players in what is a fragmented retail drugstore market. And selling hundreds of stores to chains could become labor intensive if Walgreens has to deal with small, local buyers.
According to Bloomberg Intelligence, there are some 70,000 pharmacies in the U.S., and Walgreens, CVS, and Rite Aid control a third of the market. And given that Rite Aid is more concentrated in some regions while Walgreens is truly national, antitrust regulators are likely to look at divestitures on a market by market basis.
Walgreens said it expects its acquisition of Rite Aid to close sometime in the second half of 2016.